# Dana-Farber Cancer Institute: Phase 1 study in Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer (30 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Dana-Farber Cancer Institute |
| Sponsor type | Academic and hospital |
| Study | Daraxonrasib in Resectable PDAC |
| NCT ID | NCT07898813 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Resectable Pancreatic Ductal Adenocarcinoma |
| Intervention types | drug, procedure, radiation |
| Target enrollment | 30 |
| Site countries | United States |
| Posted | 2026-10-27 |
| Planned start | 2027-04-13 |
| Event | Newly registered study |
| Event date | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07898813). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.